Coloplast A/S (OTCMKTS:CLPBY) Announces Earnings Results, Misses Expectations By $0.01 EPS

Coloplast A/S (OTCMKTS:CLPBY) issued its earnings results on Tuesday. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01), Zacks reports. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. Coloplast A/S updated its FY 2025 guidance to EPS.

Coloplast A/S Price Performance

Shares of OTCMKTS:CLPBY opened at $11.13 on Wednesday. Coloplast A/S has a 52-week low of $10.63 and a 52-week high of $14.34. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.66 and a current ratio of 1.02. The business has a 50-day moving average price of $11.43 and a 200-day moving average price of $12.56.

Coloplast A/S Increases Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were issued a $0.2435 dividend. The ex-dividend date of this dividend was Monday, December 9th. This is a boost from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s dividend payout ratio (DPR) is currently 93.94%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CLPBY. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th. Finally, Sanford C. Bernstein raised shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.